# A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct04036682/  
OnCo record `nct04036682` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Zipalertinib in non-small-cell lung cancer and small-cell lung cancer, run by Cullinan Therapeutics Inc., active and no longer recruiting.

## Summary

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT04036682 by Cullinan Therapeutics Inc., with 284 participants planned, started 2019-10-31 and due to reach its primary completion in 2025-10-13. Interventions recorded: CLN-081. Conditions listed: Non Small Cell Lung Cancer, EGFR Exon 20 Mutation. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04036682
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
- Sponsor: Cullinan Therapeutics Inc.
- Enrolled: 284

## Sources

- ClinicalTrials.gov NCT04036682: https://clinicaltrials.gov/study/NCT04036682

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Zipalertinib](https://onco.cc/drugs/zipalertinib/)
- companies: [Cullinan Therapeutics](https://onco.cc/companies/cullinan-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04036682.json